Scientific foundation and possible implications for practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site andSystemic Implementation of AngioX (MATRIX) trial
Trial design and rationale paper published in Journal of cardiovascular translational research (2014)
Abstract
Early invasive management and the use of combined antithrombotic therapies have decreased the risk of recurrent ischaemia in patients with acute coronary syndrome (ACS) but have also increased the bleeding risk. Transradial intervention (TRI) and bivalirudin infusion compared to transfemoral intervention (TFI) or unfractionated heparin (UFH) plus glycoprotein IIb/IIIa inhibitors (GPI) decrease bleeding complications in patients with ACS. To what extent, a bleeding preventive strategy incorporating at least one of these two treatment options translates into improved outcomes is a matter of debate. The Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX study is a large-scale, multicenter, prospective, open-label trial, conducted at approximately 100 sites in Europe aiming to primarily assess whether TRI and bivalirudin infusion, as compared to TFI and UFH plus provisional GPI, decrease the 30-day incidence of death, myocardial infarction or stroke across the whole spectrum of ACS patients.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
The MATRIX trial is a multicenter European study comparing transradial intervention plus bivalirudin against transfemoral intervention plus unfractionated heparin with provisional glycoprotein IIb/IIIa inhibitors. It will assess 30-day death, myocardial infarction, and stroke across the full ACS spectrum.
Why This Matters for Hirudotherapy
This article outlines the scientific foundation and design of the MATRIX trial, a large-scale, multicenter, prospective, open-label trial conducted at approximately 100 sites in Europe, evaluating transradial intervention and bivalirudin infusion versus transfemoral intervention with unfractionated heparin plus provisional glycoprotein IIb/IIIa inhibitors for acute coronary syndrome. The trial aims to assess whether this approach decreases the 30-day incidence of death, myocardial infarction, or stroke across the spectrum of acute coronary syndrome patients. Bivalirudin (formerly Hirulog) is a synthetic peptide anticoagulant designed partly on the C-terminal sequence of hirudin, the anticoagulant of the medicinal leech (Maraganore et al., 1990); this paper studies the drug, not leech therapy.
Citation
Reference (Vancouver style)
Valgimigli M, Calabrò P, Cortese B, Frigoli E, Garducci S, Rubartelli P, et al. Scientific foundation and possible implications for practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site andSystemic Implementation of AngioX (MATRIX) trial. J Cardiovasc Transl Res. 2014;7(1):101-111. doi:10.1007/s12265-013-9537-1. PMID: 24395497
Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.
Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026